| Black, Peter C |
TURBT, NCT06111235: A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following |
|
|
| Recruiting | 3 | 364 | Canada, US | Cretostimogene Grenadenorepvec, CG0070, n-dodecyl-B-D-maltoside, DDM | CG Oncology, Inc. | Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma | 01/28 | 01/30 | | |
| Not yet recruiting | 2/3 | 688 | Canada | Active Surveillance, Clinical restaging (utDNA, ctDNA, MRI and TURBT), Control arm - Definitive bladder treatment | Peter Black, University of British Columbia, Canadian Institutes of Health Research (CIHR) | Muscle-Invasive Bladder Carcinoma | 12/27 | 12/28 | | |
NCT06124976: Multicenter Clinical Trial of ST-02 for Ablation of Upper Tract Urothelial Carcinoma |
|
|
| Recruiting | 2/3 | 70 | Canada | ST-02 | University of British Columbia | Urothelial Carcinoma of the Renal Pelvis and Ureter, Transitional Cell Cancer of the Renal Pelvis and Ureter | 04/26 | 04/26 | | |
SWOG S1605, NCT02844816: Atezolizumab in Treating Patients With Recurrent BCG-Unresponsive Non-muscle Invasive Bladder Cancer |
|
|
| Active, not recruiting | 2 | 172 | Canada, US | Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG 7446, RG-7446, RG7446, RO 5541267, RO-5541267, RO5541267, Tecentriq | National Cancer Institute (NCI), Canadian Cancer Trials Group | Recurrent Bladder Urothelial Carcinoma, Stage 0a Bladder Urothelial Carcinoma AJCC v6 and v7, Stage 0is Bladder Urothelial Carcinoma AJCC v6 and v7, Stage I Bladder Urothelial Carcinoma AJCC v6 and v7 | 06/23 | 09/25 | | |
|
NCT03945162: Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients |
|
|
| Recruiting | 2 | 125 | Canada, US | Ruvidar® (TLD-1433) Bladder infusion and PDT | Theralase® Technologies Inc., University Health Network, Toronto, Pharma eMarket | Non-Muscle Invasive Bladder Cancer ("NMIBC") Unresponsive/Intolerant to BCG | 06/25 | 12/25 | | |
Rideau, NCT05120622: Trial of Local Cystoscopic Injection of Tremelimumab Plus Systemic Durvalumab for High Risk Non-Muscle Invasive Bladder Cancer |
|
|
| Withdrawn | 1/2 | 48 | Canada | Tremelimumab | University of British Columbia | Bladder Cancer, High-Risk Cancer, Tremelimumab, Durvalumab, Non-muscle Invasive | 05/22 | 05/22 | | |
EMMPC, NCT02481648: Feasibility of Measuring Exercise's Effects on Molecular Mechanisms of Disease Progression in Prostate Cancer |
|
|
| Active, not recruiting | N/A | 20 | Canada | Exercise | Vancouver Prostate Centre | Prostate Cancer | 12/18 | 12/24 | | |
LS-URO, NCT06218433: Urothelial Cancer Screening in Individuals With Lynch Syndrome Using a Urine Tumor DNA Panel ( Study) |
|
|
| Recruiting | N/A | 200 | Europe, Canada | Urothelial cancer screening using urine tumor DNA test, Urothelial cancer screening using urine cytology (comparator) | Tampere University Hospital, Tampere University | Urothelial Carcinoma, Lynch Syndrome | 04/25 | 12/34 | | |
UROSCOUT-1, NCT06310759: Prospective Validation Study of High Volume Urine DNA Testing in Individuals with Suspicion of Urothelial Cancer |
|
|
| Recruiting | N/A | 3000 | Europe, Canada, Japan, US | | Tampere University Hospital, Tampere University | Urothelial Carcinoma | 12/26 | 12/29 | | |
NCT03988309: STRATA: Safe Testing of Risk for AsymptomaTic MicrohematuriA |
|
|
| Active, not recruiting | N/A | 554 | Canada, US | Cxbladder | Pacific Edge Limited | Hematuria, Urothelial Carcinoma | 12/24 | 12/24 | | |
| Järvinen, Riikka |
| Active, not recruiting | 3 | 400 | Europe | white light TUR-BT, blue light TUR-BT, optimized MMC, optimized mitomycin-C, single immediate chemotherapy instillation, single instillation | Turku University Hospital, Finnbladder | Bladder Cancer | 12/21 | 08/23 | | |
NCT03664869: Electromotive Mitomycin-C (EMDA-MMC) in Preventing Recurrences in High-risk Non-muscle-invasive Bladder Cancer |
|
|
| Recruiting | 3 | 300 | Europe | BCG instillation therapy, BCG, BCG-MEDAC, OncoTICE, ImmuCyst, TheraCys, Sequential BCG and EMDA mitomycin C, Sequential BCG and EMDA-MMC | Turku University Hospital, Finnbladder | Bladder Cancer | 11/25 | 11/25 | | |
UROSCOUT-1, NCT06310759: Prospective Validation Study of High Volume Urine DNA Testing in Individuals with Suspicion of Urothelial Cancer |
|
|
| Recruiting | N/A | 3000 | Europe, Canada, Japan, US | | Tampere University Hospital, Tampere University | Urothelial Carcinoma | 12/26 | 12/29 | | |
| Recruiting | N/A | 100 | Europe | Personalised treatment | Helsinki University Central Hospital, Karolinska Institutet | Prostate Carcinoma, Kidney Cancer, Urothelial Carcinoma, Testicular Cancer, Penile Cancer | 12/25 | 12/25 | | |
| Seppänen, Marjo |
| Active, not recruiting | 3 | 400 | Europe | white light TUR-BT, blue light TUR-BT, optimized MMC, optimized mitomycin-C, single immediate chemotherapy instillation, single instillation | Turku University Hospital, Finnbladder | Bladder Cancer | 12/21 | 08/23 | | |
| Recruiting | N/A | 600 | Europe | A shared decision making | Turku University Hospital, Tampere University Hospital, Satakunta Central Hospital, Central Finland Hospital District, Memorial Sloan Kettering Cancer Center, Mount Sinai Hospital, New York | Prostate Cancer | 12/21 | 12/41 | | |
UROSCOUT-1, NCT06310759: Prospective Validation Study of High Volume Urine DNA Testing in Individuals with Suspicion of Urothelial Cancer |
|
|
| Recruiting | N/A | 3000 | Europe, Canada, Japan, US | | Tampere University Hospital, Tampere University | Urothelial Carcinoma | 12/26 | 12/29 | | |
| Haapiainen, Henry |
UROSCOUT-1, NCT06310759: Prospective Validation Study of High Volume Urine DNA Testing in Individuals with Suspicion of Urothelial Cancer |
|
|
| Recruiting | N/A | 3000 | Europe, Canada, Japan, US | | Tampere University Hospital, Tampere University | Urothelial Carcinoma | 12/26 | 12/29 | | |
